Core Viewpoint - The company, Yaoshi Technology, reported a significant revenue growth from MNC clients in the first half of the year and anticipates this trend to continue in the second half, supported by strategic collaborations and technological advancements [1] Group 1: Revenue Growth - The revenue from MNC clients has shown rapid growth in the first half of the year [1] - The company expects to maintain this revenue growth trend in the second half based on current order status [1] Group 2: Strategic Development - The company plans to deepen the integration of low-carbon chemical technology and digital intelligence technology in R&D and production [1] - Strategic cooperation with MNC clients will be further enhanced, pushing more projects into late clinical and commercialization stages [1] Group 3: Customer Focus - The company is focusing on strategic customer service to improve business response efficiency through the capabilities upgrade of the "iron triangle" team [1] - The company expresses confidence in maintaining a growth trend in the near future due to the synergistic effects of technology empowerment, project advancement, and new business expansion [1]

Group 1: Financial Performance - The company achieved a revenue of 920 million yuan in the first half of 2025, representing a year-on-year growth of 23.48% [2] - The net cash flow from operating activities was 467 million yuan, an increase of 240.62% compared to the same period last year [3] - The gross profit margin has shown a slight improvement of 1.4 percentage points from Q1 to Q2, indicating a stabilization trend [3] Group 2: Strategic Focus and Business Development - The company is focusing on three key strategies: concentrating on strategic clients, enhancing technological innovation, and expanding new business growth areas [2] - There has been a 19.88% year-on-year increase in new orders for CDMO business [3] - Revenue from multinational pharmaceutical companies (MNCs) increased by 69.73% year-on-year, reflecting deepening collaborations [3] Group 3: Operational Efficiency and Cost Management - The company is maintaining a capacity utilization rate of 60%-70% in mature workshops, which is considered a reasonable industry level [4] - Cost control measures are being strengthened to balance between cost management and strategic development [3] - The company has implemented various cost-reduction and efficiency-enhancing measures since the second half of last year [5] Group 4: Future Outlook and Market Trends - The company anticipates continued revenue growth in the second half of the year, supported by a favorable order backlog and market demand recovery [4] - There is a plan to expand fixed asset investments to meet the growing demand for new molecular drugs [6] - The company is confident in stabilizing and gradually returning the gross profit margin to an ideal level [5] Group 5: AI and Technological Integration - The company has systematically integrated AI applications across multiple business areas, generating over 80 million novel molecular blocks [10] - AI tools are being utilized to enhance operational efficiency, particularly in project reporting and document processing [10] - Future plans include expanding AI investments and deploying automated laboratory and robotic equipment [10]

Group 1: Company Performance and Growth - In 2024, the company experienced a 30% year-on-year growth in API and GMP intermediate projects at Zhejiang Huishi, with 4 new NDA projects added [3] - The CDMO new signed order amount in 2024 increased by 12.43%, with order quantity rising by 31.12% [9] - The company’s revenue from multinational pharmaceutical companies grew by 16.37%, contributing 27.50% to total revenue [9] Group 2: Market Expansion and Client Acquisition - The company has established a 5-person BD team in Europe and appointed a BD head for Japan and South Korea to enhance market share [2] - By the end of 2024, the company entered multiple top 10 multinational pharmaceutical companies' direct procurement platforms, significantly boosting sales [8] - The company aims to increase the application of new technologies in production from 20% in 2024 to 30% or higher [4] Group 3: Financial Metrics and Cost Management - The gross margin for the CDMO business in 2024 was 31.57%, expected to remain stable in Q1 2025 [10] - The company plans to maintain stable absolute amounts for expenses in 2025 while reducing expense ratios alongside revenue growth [14] - The human resource cost accounted for 35.30% of revenue, with a 14.69% increase in fixed asset depreciation impacting overall costs [17] Group 4: Product Development and Innovation - The company is focusing on developing new molecular building blocks for small molecule GLP-1 projects, leveraging early market positioning [15] - The R&D team is enhancing efficiency by utilizing AI technology for new product design starting in 2024 [8] - The company plans to expand its R&D capabilities at the Nanjing center to support future business growth [12] Group 5: Response to Market Conditions - The company is closely monitoring changes in U.S. tariff policies, with 70% of revenue from U.S. and European clients, and 20% directly from the U.S. market [6][7] - The company is implementing strategies to mitigate the impact of tariff fluctuations, including enhancing European market presence and optimizing contract terms [7] - The company anticipates structural pressures on demand from small biotech companies due to global investment cycles [9]